Çѱ¹º´¿ø¾à»çȸ
·Î±×ÀÎ
Àüü¸Þ´º
·Î±×ÀÎÇϼ¼¿ä
¸Þ´º´Ý±â
º´¿ø¾à»çȸ ¼Ò°³
ÇÏÀ§¸Þ´º¿±â
ȸÀåÀλ縻
¹Ì¼Ç°úºñÀü
CI ¼Ò°³
º´¿ø¾àÇкаúÇùÀÇȸ
ÇÏÀ§¸Þ´º¿±â
ÇùÀÇȸ ¼Ò°³
ºÐ°úº° ¼Ò°³
ã¾Æ¿À½Ã´Â±æ
¸¶ÀÌÆäÀÌÁö
ÇÏÀ§¸Þ´º¿±â
¸¶ÀÌÆäÀÌÁö
ȸ¿øÁ¤º¸°ü¸®
±³À°½Åû
¿¬¼ö±³À°ÆòÁ¡
±³À°/Çмú¸¶´ç
ÇÏÀ§¸Þ´º¿±â
Çмú´ëȸ
ÇÏÀ§¸Þ´º¿±â
Ãá°è Çмú´ëȸ
Ãß°è Çмú´ëȸ
Çмú¼¼¹Ì³ª
Àü¹®¾à»ç °øÅë±³À°
ÇÏÀ§¸Þ´º¿±â
ÀÓ»ó¾àÇÐ ¿¬¼ö±³À°
Àü¹®¾à»ç¿ªÇÒ
ÀǾàÅë°è
ÀÓ»ó¾àµ¿ÇÐ
ÀǾàÁ¤º¸
ÇÁ¸®¼ÁÅÍ ±³À°
ÇÏÀ§¸Þ´º¿±â
½Ç¹«±³À°°»ç ¾ç¼º±³À°
Àü¹®¿ª·® °È±³À° (I)
Àü¹®¿ª·® °È±³À° (II)
¿¬¼ö±³À°
ÇÏÀ§¸Þ´º¿±â
°ü¸®ÀÚ
Áß°£°ü¸®ÀÚ
½Å±Ô¾à»ç
º´¿ø¾àÇкаú
ÇÏÀ§¸Þ´º¿±â
°¨¿°¾à·á
񃧯
³»ºÐºñ¾à·á
񃧯
½ÉÈ
³ëÀξà·á
½ÉÈ
º¹¾àÁöµµ
񃧯
¼Ò¾Æ¾à·á
񃧯
½ÉÈ
½ÉÇ÷°ü°è¾à·á
񃧯
½ÉÈ
¾à¹°°æÁ¦¼ºÆò°¡
񃧯
½ÉÈ
¾à¹°ºÎÀÛ¿ë
񃧯
½ÉÈ
¿µ¾ç¾à·á
񃧯
½ÉÈ
ÀǾàÁ¤º¸
񃧯
½ÉÈ
ÀÓ»ó½ÃÇè
񃧯
ÀÓ»ó¾àµ¿ÇÐ
½ÉÈ
Àå±âÀ̽ľà·á
񃧯
½ÉÈ
Á¾¾ç¾à·á
񃧯
½ÉÈ
ÁßȯÀÚ¾à·á
½ÉÈ
º´¿ø¾àÇкаú ½ÉÆ÷Áö¾ö
ÇÏÀ§¸Þ´º¿±â
ÁßȯÀÚ¾à·á ½Éȱ³À°
¿µ¾ç¾à·á ½Éȱ³À°
°øµ¿ ½Éȱ³À°
ÀÓ»ó½ÃÇè Á¾»çÀÚ±³À°
±âŸ±³À°
ÇÏÀ§¸Þ´º¿±â
¸¶¾à·ù °ü¸®
ÀÇ·á±â°ü ÀÎÁõÆò°¡
º´¿ø¾à»çȸÁö
¾Ë¸²¸¶´ç
ÇÏÀ§¸Þ´º¿±â
°øÁö»çÇ×
°í½Ã ¹× °ø°í
ȸ¿øµ¿Á¤/º´¿ø¼Ò½Ä
»õ¼Ò½Ä
Æ÷ÅäÁ¸
À̽´º¸µå
Çà»çÀÏÁ¤
ÇÏÀ§¸Þ´º¿±â
ÀÌ´ÞÀÇ ÁÖ¿äÀÏÁ¤
±³À°¤ýÇмú Çà»çÀÏÁ¤
ÇØ¿ÜÇÐȸ ÀÏÁ¤
Ä¿¹Â´ÏƼ
ÇÏÀ§¸Þ´º¿±â
ȸ¿ø°Ô½ÃÆÇ
±¸ÀÎ/±¸Á÷
º¸¹°Ã¢°í
¹®ÀÇÀüÈ : 02-583-0887
ÆÑ½º¹øÈ£ : 02-521-5629
(06649) ¼¿ï½Ã ¼Ãʱ¸ »çÀÓ´ç·Î 5
Çùȸ
¼Ò°³
¸¶ÀÌ
ÆäÀÌÁö
±³À°
Çмú
¾Ë¸²
¸¶´ç
Çà»ç
ÀÏÁ¤
Ä¿¹Â
´ÏƼ
ȸÀåÀλ縻
¹Ì¼Ç°úºñÀü
CI ¼Ò°³
º´¿ø¾àÇкаúÇùÀÇȸ
ÇùÀÇȸ ¼Ò°³
ºÐ°úº° ¼Ò°³
ã¾Æ¿À½Ã´Â±æ
¸¶ÀÌÆäÀÌÁö
ȸ¿øÁ¤º¸°ü¸®
±³À°½Åû
±³À°ÆòÁ¡È®ÀÎ
Çмú´ëȸ
Ãá°è Çмú´ëȸ
Ãß°è Çмú´ëȸ
Çмú¼¼¹Ì³ª
Àü¹®¾à»ç °øÅë±³À°
ÀÓ»ó¾àÇÐ ¿¬¼ö±³À°
Àü¹®¾à»ç¿ªÇÒ
ÀǾàÅë°è
ÀÓ»ó¾àµ¿ÇÐ
ÀǾàÁ¤º¸
ÇÁ¸®¼ÁÅÍ ±³À°
½Ç¹«±³À°°»ç ¾ç¼º±³À°
Àü¹®¿ª·® °È±³À° (I)
Àü¹®¿ª·® °È±³À° (II)
¿¬¼ö±³À°
°ü¸®ÀÚ
Áß°£°ü¸®ÀÚ
½Å±Ô¾à»ç
º´¿ø¾àÇкаú
°¨¿°¾à·á
񃧯
³»ºÐºñ¾à·á
񃧯
½ÉÈ
³ëÀξà·á
½ÉÈ
º¹¾àÁöµµ
񃧯
¼Ò¾Æ¾à·á
񃧯
½ÉÈ
½ÉÇ÷°ü°è¾à·á
񃧯
½ÉÈ
¾à¹°°æÁ¦¼ºÆò°¡
񃧯
½ÉÈ
¾à¹°ºÎÀÛ¿ë
񃧯
½ÉÈ
¿µ¾ç¾à·á
񃧯
½ÉÈ
ÀǾàÁ¤º¸
񃧯
½ÉÈ
ÀÓ»ó½ÃÇè
񃧯
ÀÓ»ó¾àµ¿ÇÐ
½ÉÈ
Àå±âÀ̽ľà·á
񃧯
½ÉÈ
Á¾¾ç¾à·á
񃧯
½ÉÈ
ÁßȯÀÚ¾à·á
½ÉÈ
º´¿ø¾àÇкаú ½ÉÆ÷Áö¾ö
ÁßȯÀÚ¾à·á ½Éȱ³À°
¿µ¾ç¾à·á ½Éȱ³À°
°øµ¿ ½Éȱ³À°
ÀÓ»ó½ÃÇè Á¾»çÀÚ±³À°
±âŸ±³À°
¸¶¾à·ù °ü¸®
ÀÇ·á±â°ü ÀÎÁõÆò°¡
º´¿ø¾à»çȸÁö
°øÁö»çÇ×
°í½Ã ¹× °ø°í
ȸ¿øµ¿Á¤/º´¿ø¼Ò½Ä
»õ¼Ò½Ä
Æ÷ÅäÁ¸
À̽´º¸µå
ÀÌ´ÞÀÇ ÁÖ¿äÀÏÁ¤
±³À°¤ýÇмú Çà»çÀÏÁ¤
ÇØ¿ÜÇÐȸ ÀÏÁ¤
ȸ¿ø°Ô½ÃÆÇ
±¸ÀÎ/±¸Á÷
º¸¹°Ã¢°í
º´¿ø¾à»çȸÁö
ȸÁö¸ñ·Ï
»ó¼¼°Ë»ö
2022³â (Vol.39)
2021³â (Vol.38)
2020³â (Vol.37)
2019³â (Vol.36)
2018³â (Vol.35)
2017³â (Vol.34)
2016³â (Vol.33)
2015³â (Vol.32)
2014³â (Vol.31)
2013³â (Vol.30)
2012³â (Vol.29)
2011³â (Vol.28)
2010³â (Vol.27)
2009³â (Vol.26)
2008³â (Vol.25)
2007³â (Vol.24)
2006³â (Vol.23)
2005³â (Vol.22)
2004³â (Vol.21)
2003³â (Vol.20)
2002³â (Vol.19)
2001³â (Vol.18)
2000³â (Vol.17)
1999³â (Vol.16)
1998³â (Vol.15)
1997³â (Vol.14)
1996³â (Vol.13)
1995³â (Vol.12)
1994³â (Vol.11)
1993³â (Vol.10)
1992³â (Vol.9)
1991³â (Vol.8)
1990³â (Vol.7)
1989³â (Vol.6)
1988³â (Vol.5)
1987³â (Vol.4)
1986³â (Vol.3)
1985³â (Vol.2)
1984³â (Vol.1)
01
02
03
04
05
06
Article 2022³â Vol.39 No.02
[ƯÁý] ¹Ì¸¸¼º °Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾¿¡¼ CAR-T¼¼Æ÷ Ä¡·áÀÇ ÀÌÇØ¿Í Àû¿ë
À±»óÀº(¼º±Õ°ü´ëÇб³ »ï¼º¼¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú)
[³í¹®] COVID-19 ÁßȯÀÚ¿¡¼ ¿¹¹æÀû Ç×ÀÀ°íÁ¦ »ç¿ë ¹× ÃâÇ÷ °ü·Ã ¾à¹°ÀÌ»ó¹ÝÀÀ ¹ß»ý ÇöȲ º¸°í(Prophylactic Anticoagulant Use and Adverse Events with
Bleeding in Critically Ill COVID-19 Patients)
¹æ¼±¾Æa, ±èÇü¼÷a, Á¤¿µ¹Ìa, ÀÌÁ¤Èa, ÀÌÁÖ¿¬b, ±èÀº°æb¢Ó(ºÐ´ç¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎa, ¼¿ï´ëÇб³ ¾àÇдëÇÐb)
[³í¹®] ºÒÇö¼º °©»ó¼±±â´ÉÀúÇÏÁõ ³ëÀΠȯÀÚ¿¡¼ Levothyroxine Ä¡·á È¿°ú ºÐ¼® (Analysis of the Effect of Levothyroxine Treatment in Elderly Patients with Subclinical Hypothyroidism)
±è°æÀº, µµ¹ÎÈñ, ±Ý¹ÎÁ¤, ±èÀç¼Û, ¼ÕÀº¼±¢Ó, À¯À±¹Ìa,¢Ó(¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ¾à¹«±¹, ¿¬¼¼´ëÇб³ ¾àÇдëÇÐa)
[³í¹®] Irinotecan¿¡ ÀÇÇÑ ±Þ¼º Äݸ°¼º ÁõÈıº ¿¹¹æ ¸ñÀûÀÇ Atropine Åõ¿© ÀûÀý¼º Æò°¡ (Evaluation of the Effectiveness of Atropine Administration
for Prevention of Acute Cholinergic Syndrome Associated with Irinotecan)
ÃÖÀ¯¿Á¢Ó, Á¶Àº¾Æ, À̼ÒÈñ, ¹Ú¾Ö·É, À±Á¤ÀÌ, °Áø¼÷(°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ)
[³í¹®] The Present Status of Drug Administration via Enteral Route in a Tertiary Hospital : A Cross-Sectional Study
À̼±¹Î(ÀÎÇÏ´ëÇб³º´¿ø ¾àÁ¦ºÎ)
[³í¹®] Àå±â°£ Ç×±ÕÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ º¸°í(Report on Implementing Antimicrobial Stewardship Program for Long Term Antimicrobial Use)
¹ÚÈ¿Á¤a,b*¢Ó, ±èÁøa*, ¼ÕÀ¯¹Îa,b, ÀÌÀçÇöa, À̿뼮a, ¹Î¸í¼÷a, Çã°æ¹Îc¢Ó(»ï¼º¼¿ïº´¿ø ¾àÁ¦ºÎa, ¼º±Õ°ü´ëÇб³ ¾àÇдëÇÐb, »ï¼º¼¿ïº´¿ø °¨¿°³»°úc)
[³í¹®] ±¹³» ÀÓ»ó½ÃÇè ´ë»óÀÚ ¸ðÁý ±¤°í¹® ³»¿ë ºÐ¼®°ú Æò°¡ (Assessment and Analysis of Recruitment Resources for Clinical Trial Subjects in Korea)
±èÇöÁøa,b, ÇÑÇý¼ºb, ¼ÕÇö¼øb¢Ó(Â÷ÀǰúÇдëÇб³ ÀÏ»êÂ÷º´¿øa, Â÷ÀǰúÇдëÇб³ ¾àÇдëÇÐb)
[¾÷¹«°³¼±»ç·Ê] ½Å±â´É ÀúÇÏ È¯ÀÚ¿¡ ´ëÇÑ ¾à»çÀÇ Ã³¹æ°ËÅä ¹× Ã³¹æÁßÀç ¾÷¹« ¼Ò°³
ÀÌÀ¯Á¤, ÃÖÀÎÈ, ±è¼¼Áö, À±µµ°æ, ¹è¼ºÁø(ºÎ»ê´ëÇб³º´¿ø ¾àÁ¦ºÎ)
[Çмú°ÁÂ] [¹®Á¦Æ÷ÇÔ] ÇâÁ¤½Å¼ºÀǾàǰÀÇ ¾ÈÀüÇÑ »ç¿ë°ú ¾à»çÀÇ ¿ªÇÒ
Á¦³²°æ(ºÎ»ê´ëÇб³ ¾àÇдëÇÐ)
1